BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Business

  Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

  Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024.

  February 1, 2024

   · 

  1 min read
• Genetown

  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2024

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 26,850 restricted stock units to seven newly-hired employees.

  February 1, 2024

   · 

  2 min read
• Business

  AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) today announced that it will report its fourth quarter and full year 2023 financial results after the close of the U.S. financial markets on Thursday, February 22, 2024.

  February 1, 2024

   · 

  2 min read
• Biotech Beach

  Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February

  Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at two upcoming investor conferences in February.

  February 1, 2024

   · 

  5 min read
• Business

  Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - February 1, 2024

  Oncternal Therapeutics, Inc. today announced the approval of an inducement award to one new employee, Damien Bresson, who is joining Oncternal as Senior Director, Preclinical and Translation Science.

  February 1, 2024

   · 

  3 min read
• Pharm Country

  Curemark Announces the Addition of Christopher Varelas to the Board of Directors

  Curemark, LLC announced the appointment of Chris Varelas to its Board of Directors. Mr. Varelas is a Co-founding Partner of Riverwood Capital, an investment firm focused on high-growth technology and technology-related companies.

  February 1, 2024

   · 

  3 min read
• Biotech Bay

  Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

  Nurix Therapeutics, Inc. announced the publication of a manuscript in the journal Science titled: “Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127”.

  February 1, 2024

   · 

  8 min read
• Business

  Penumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024

  Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2023 after market close on Thursday, February 22, 2024 at 4:30 PM Eastern Time.

  February 1, 2024

   · 

  1 min read
• Business

  AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

  Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after the close of the U.S. financial markets.

  February 1, 2024

   · 

  2 min read
• Business

  Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results

  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2023 financial results will be released on Thursday, February 15, 2024 after the market closes.

  February 1, 2024

   · 

  1 min read